Understand the source comparison
Real Peptides GHRP-2 Acetate vs Competitors Quality: Research-Grade Comparison
HPLC Purity (verified) 98.2–99.1% (third-party CoA included) 95–97% (in-house report, no CoA) 90–95% (claimed, untested) Real Peptides consistently exceeds research-grade threshold with independent verification. Budget suppliers rarely provide testable documen
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- HPLC Purity (verified)
- 98.2–99.1% (third-party CoA included)
- 95–97% (in-house report, no CoA)
- 90–95% (claimed, untested)
- Real Peptides consistently exceeds research-grade threshold with independent verification. Budget suppliers rarely provide testable documentation
- Synthesis Method
- Small-batch SPPS with real-time UV monitoring
- Automated SPPS, batch verification only
- Large-batch synthesis, minimal QC
- Small-batch allows in-process error correction. Large-batch pushes through coupling failures that reduce bioactivity
- Salt Form
- Acetate (low hygroscopicity, stable 24+ months at −20°C)
- TFA or free base (hygroscopic, 12–18 month stability)
- Unspecified or chloride salt (unstable)
- Acetate salt significantly extends shelf life and reduces aggregation during reconstitution
- Residual Moisture (post-lyophilisation)
- <2% (Karl Fischer verified)
- 3–4% (not disclosed)
- 4–6% (not tested)
- Moisture above 3% accelerates degradation. Real Peptides' <2% standard preserves bioactivity during storage
- Endotoxin Level
- <0.01 EU/mg (LAL tested, documented)
- 0.1–0.5 EU/mg (not disclosed)
- Not tested
- Endotoxin contamination above 0.1 EU/mg triggers immune artifacts in cell culture. Real Peptides' <0.01 standard prevents false-positive results
- Molecular Weight Confirmation
- 817.9 Da (mass spec verified, third-party)
- Mass spec performed (in-house, no independent verification)
- Not verified
- Independent mass spec confirmation eliminates sequence error risk. Critical for studies requiring exact molecular targeting